FTSE MIB
34.249,77 +310,02 (+0,91%) Dow Jones
38.239,66 +153,86 (+0,40%) Nasdaq
15.927,90 +316,14 (+2,03%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
83,66 +0,09 (+0,11%) Bitcoin EUR
59.659,88 +749,88 (+1,27%)
Ionis Pharmaceuticals, Inc. (0JDI.L)
| Chiusura precedente | 41,86 |
| Aperto | 41,50 |
| Denaro | 0,00 x N/D |
| Lettera | 0,00 x N/D |
| Min-Max giorno | 41,50 - 42,13 |
| Intervallo di 52 settimane | 33,21 - 53,94 |
| Volume | |
| Media Volume | 351 |
| Capitalizzazione | 58,356M |
| Beta (5 anni mensile) | 0,40 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -0,03 |
| Prossima data utili | 07 mag 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | N/D |
GlobeNewswirePraxis Precision Medicines Provides Portfolio Update at 2023 R&D Day
Positive results from preliminary analysis of PRAX-222 Part 1 showed 44% median reduction in seizures after three doses for SCN2A-gain-of-function pediatric patients Phase 3 (Essential3) program for ulixacaltamide initiating this quarter with mADL11 as primary endpoint; nearly 600 patients have already expressed interest in participating BOSTON, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insigh
GlobeNewswireNew Data at Cure SMA Highlight Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy
Interim results from the RESPOND study show improved motor function in most participants treated with SPINRAZA after Zolgensma® (onasemnogene abeparvovec)Biogen also reported new real-world evidence and progress on the development of a novel device to enhance the patient treatment experience CAMBRIDGE, Mass., June 30, 2023 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) announced new SPINRAZA® (nusinersen) data aimed at answering critical questions for the spinal muscular atrophy (SMA) community.
